Sutent Gets European Approval for New Indication

Pfizer Inc. announced Thursday that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression in adults.
CNBC